# Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

> **NCT06434662** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 34 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy

## Interventions

- **DRUG:** mitoxantrone hydrochloride liposome
- **DRUG:** Cytarabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06434662
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434662, "Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06434662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*